RADIATION THERAPY ONCOLOGY GROUP
RTOG 1102
A PHASE I STUDY OF INDUCTION GANITUMAB (IND #113278) AND GEMCITABINE, FOLLOWED BY GANITUMAB, CAPECITABINE, AND 3D-CONFORMAL RADIATION THERAPY (3D-CRT) WITH SUBSEQUENT MAINTENANCE THERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER
RTOG 1102
A PHASE I STUDY OF INDUCTION GANITUMAB (IND #113278) AND GEMCITABINE, FOLLOWED BY GANITUMAB, CAPECITABINE, AND 3D-CONFORMAL RADIATION THERAPY (3D-CRT) WITH SUBSEQUENT MAINTENANCE THERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER
Protocol Participation Information
- Credentialing
- Facility Questionnaire: Part I is required for this protocol.
- Download fillable form and complete it.
- Submit to RTOG RT Quality Assurance Department
Email: rtog-facquest@phila.acr.org Fax: 215-940-8817
- Facility Questionnaire: Part I is required for this protocol.
- Data Submission
- Digital Data Submission Procedures
- Digital Data Submission Information (DDSI) Form
- Data Submission Check list
- ATC Compliant Treatment Planning Systems
- Structure Names
- Protocol Text (http://www.rtog.org/)
- Study Details Page (http://www.rtog.org/)
Back to protocols
